RxDoctor Payments Data

William Capo, MD

Cardiovascular Disease · Tampa, FLNPI 1356316822

Payments from drug & device makers

$40,468in general payments, 2019–2025

Across 348 payments — averaging $116.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$22K
  • Novartis$10K
  • Abbott$2K
  • Medtronic$842
  • E.r. Squibb & Sons, L.L.C.$813
  • Cvrx, Inc.$793
  • plus $4K from 23 others

What the payments were for

  • Speaking & faculty fees$28,81071%
  • Travel & lodging$100%
  • Food & beverage$11,61529%
  • Education$320%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,468 in reported general payments places this provider in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$289,550
Medicare patients
653
Services billed
2,688

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban399$346,173
EntrestoSacubitril/Valsartan236$204,689
FarxigaDapagliflozin Propanediol111$94,442
JardianceEmpagliflozin71$49,343
XareltoRivaroxaban29$34,885
MultaqDronedarone Hcl15$21,590
Repatha SureclickEvolocumab19$21,244
Repatha SyringeEvolocumab29$15,671
BrilintaTicagrelor22$11,710
Metoprolol Succinate450$5,531
Nitroglycerin135$3,378
Ranolazine ErRanolazine38$2,956
Potassium Chloride158$2,336
Carvedilol296$1,932
Propafenone Hcl13$1,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$375$346,173399 claims
NovartisEntresto$10,154$204,689236 claims
AstraZenecaFarxiga, Brilinta$21,592$106,151133 claims
Boehringer IngelheimJardiance$786$49,34371 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Tampa

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →